A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
← catalyst calendarSponsored by Lexicon Pharmaceuticals (industry) · LXRX — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
500estimated
Sites
108
Countries
Argentina, Belgium, Brazil +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-24 | actual | When the study began enrolling |
| Primary completion | Jul 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Obstructive Cardiomyopathy, Hypertrophic
- Non-obstructive Hypertrophic Cardiomyopathy
Interventions
- Drug: Sotagliflozin — also filed as SAR439954/LX4211
- Drug: Placebo — also filed as SAR439954/LX4211
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 26 in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ CSS)
measured Baseline to Week 26
Permalink · LXRX's whole pipeline · Catalyst calendar · Every registered study · What changed